Ground breaking ceremony for new 1,000m 2 multi-story building for sterile manufacturing of critical care products that play a vital role in treating anti-microbial resistant infections.
Copenhagen, Denmark, 11th October 2017 - Xellia Pharmaceuticals (‘Xellia’), a specialty pharmaceutical company focusing on providing important anti-infective treatments against serious and often life-threatening infections, has held an official ground breaking ceremony for a new US$25 million expansion at its Copenhagen site. This site houses Xellia’s headquarters and is the Company’s largest product manufacturing plant.
The ceremony which took place on 11th October 2017, was to celebrate the start of the construction of a new state-of-the-art multi-story building that will house the latest sterile manufacturing equipment and containment solutions in a purpose built environment.
Xellia’s Copenhagen site is responsible for manufacturing, stability testing and packaging of both sterile Active Pharmaceutical Ingredients (APIs) and the Finished Dosage Forms (FDFs) for anti-infectives such as vancomycin, and colistmethate sodium.
Anti-microbial resistance is one of the world’s most serious threats to human health and Xellia’s specialty anti-infective medicines are often used as a last line of defence, where all other medicines have failed. This upgrade in facilities will ensure that Xellia is able to continue to provide a reliable supply of injectable anti-infective critical care medicines and remain at the forefront of manufacturing excellence.
Carl-Åke Carlsson, Xellia’s CEO said:
“We are pleased to celebrate the ground breaking ceremony of our new building. Xellia is one of the world’s leading suppliers of specialty anti-infectives and we are committed to constantly improving our facilities so that we can continue to produce a high quality and reliable supply.”
Xellia Pharmaceuticals has an extensive portfolio of specialty anti-infectives. Since 2013, the Copenhagen site has increased its number of employees by around 150 across different functions including roles relating to manufacturing. In addition, over the past 15 months Xellia has invested significantly across several of its global sites. Recent developments include:
- Expanding production capacity for sterile injectable products in the US. In addition to Xellia’s Raleigh, North Carolina site, a new production facility in Cleveland, Ohio, received notification from the FDA in November 2016 to allow packaging and distribution of drug products at the site. Full manufacturing of products is anticipated during 2018.
- Completing the expansion of a new US$13m, 3,000m2, multi-story Centralized Laboratory Services building at Xellia’s Budapest, Hungary, manufacturing site in August this year. This will strengthen the Company’s global anti-infective product capabilities with additional product stability and release testing expertise and capabilities. The building is located next to Xellia’s current Active Pharmaceutical Ingredient (APIs) manufacturing plant.
- Significantly expanding the Product and Innovation R&D team with more than 15 new scientists and approx.1,000 m2 of new lab space at its purpose-built Centre of Excellence in Zagreb, Croatia in September 2016. The Xellia Zagreb site, now has around 100 highly skilled employees, who are working to provide solutions for improving the efficacy, safety and delivery of existing
anti-infectives, and reducing toxic side effects, to developing novel drug-device combination antimicrobial therapies.
For more information, please contact:
Carl-Åke Carlsson, CEO
Tel: +45 32 64 55 00
Instinctif Partners (International media relations)
Eileen Paul / Ashley Tapp / Melanie Toyne-Sewell
Tel: +44 (0)1260 296 500